News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,082 Results
Type
Article (42028)
Company Profile (436)
Press Release (666618)
Section
Business (208613)
Career Advice (2020)
Deals (35995)
Drug Delivery (102)
Drug Development (83485)
Employer Resources (170)
FDA (16387)
Job Trends (15072)
News (352516)
Policy (33025)
Tag
Academia (2625)
Alliances (50853)
Alzheimer's disease (1364)
Approvals (16361)
Artificial intelligence (224)
Bankruptcy (367)
Best Places to Work (11841)
Biotechnology (330)
Breast cancer (235)
Cancer (1809)
Cardiovascular disease (143)
Career advice (1683)
CAR-T (133)
Cell therapy (388)
Clinical research (67108)
Collaboration (724)
Compensation (381)
COVID-19 (2628)
C-suite (178)
Data (1702)
Diabetes (223)
Diagnostics (6357)
Earnings (86862)
Employer resources (146)
Events (114598)
Executive appointments (597)
FDA (17341)
Funding (646)
Gene therapy (274)
GLP-1 (694)
Government (4450)
Healthcare (19112)
Infectious disease (2745)
Inflammatory bowel disease (131)
Interviews (311)
IPO (16746)
Job creations (3698)
Job search strategy (1433)
Layoffs (469)
Legal (7967)
Lung cancer (263)
Manufacturing (250)
Medical device (13422)
Medtech (13427)
Mergers & acquisitions (19628)
Metabolic disorders (597)
Neuroscience (1811)
NextGen: Class of 2025 (6750)
Non-profit (4546)
Northern California (2188)
Obesity (330)
Opinion (215)
Patents (175)
People (58263)
Phase I (21079)
Phase II (29624)
Phase III (21884)
Pipeline (788)
Postmarket research (2600)
Preclinical (8977)
Radiopharmaceuticals (258)
Rare diseases (350)
Real estate (6005)
Regulatory (22417)
Research institute (2410)
Resumes & cover letters (351)
Southern California (1894)
Startups (3755)
United States (19574)
Vaccines (636)
Weight loss (231)
Date
Today (106)
Last 7 days (818)
Last 30 days (2894)
Last 365 days (35435)
2025 (5366)
2024 (36300)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (735)
Arizona (219)
Asia (38951)
Australia (6482)
California (5056)
Canada (1755)
China (418)
Colorado (230)
Connecticut (246)
Europe (85019)
Florida (729)
Georgia (171)
Illinois (478)
Indiana (270)
Maryland (776)
Massachusetts (3909)
Michigan (202)
Minnesota (347)
New Jersey (1422)
New York (1435)
North Carolina (915)
Northern California (2188)
Ohio (176)
Pennsylvania (1141)
South America (1107)
Southern California (1894)
Texas (739)
Utah (154)
Washington State (493)
709,082 Results for "adcentrx therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Adcentrx Therapeutics Appoints Meng Jiang as Chief Financial Officer
Adcentrx Therapeutics (“Adcentrx”), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today the appointment of Meng Jiang as Chief Financial Officer (CFO).
April 8, 2024
·
2 min read
Drug Development
Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors
Adcentrx Therapeutics (“Adcentrx”) announced today that China National Medical Products Administration (NMPA) has cleared Adcentrx’s Investigational New Drug (IND) application for ADRX-0706 which enables the company to include China-based clinical centers in the ongoing Phase 1a/1b study for the treatment of select advanced solid tumors.
May 6, 2024
·
3 min read
Press Releases
Adcentrx Therapeutics Doses First Patient in Phase 1b Expansion Cohorts with ADRX-0706 Nectin-4 ADC
December 3, 2024
·
3 min read
Business
Adcentrx Therapeutics Announces Formation of Scientific Advisory Board
September 10, 2024
·
4 min read
Press Releases
Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
January 7, 2025
·
2 min read
Biotech Beach
Adcentrx Therapeutics to Present Preclinical Data for Nectin-4 ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
Adcentrx Therapeutics (“Adcentrx”) today announced that preclinical data for ADRX-0706 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA.
April 1, 2024
·
3 min read
Press Releases
Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
October 21, 2024
·
2 min read
Biotech Beach
Adcentrx Announces Extension of Series A+ Financing to $51 Million
Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announced the extension of its Series A+ financing.
December 5, 2023
·
3 min read
Biotech Beach
Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors
Adcentrx Therapeutics today announced the first patient dosed in the Phase 1a/b study of ADRX-0706 for the treatment of advanced solid tumors.
September 27, 2023
·
2 min read
Biotech Beach
Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures
Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announces the closing of a $38 million Series A+ financing.
April 24, 2023
·
6 min read
1 of 70,909
Next
